Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Optimum bowel cleansing before colonoscopy

This month's issue of the American Journal of Gastroenterology examines a dual-action, low-volume bowel cleanser administered the day before colonoscopy.

News image

Optimal bowel preparation is vital for the efficacy and safety of colonoscopy.

The inconvenience, discomfort, required consumption of large volumes of product, and potential adverse effects associated with some bowel preparations deter patients from colonoscopy, and may provide inadequate cleansing.

A dual-action, non-phosphate, natural orange-flavored, low-volume preparation containing sodium picosulfate and magnesium citrate (P/MC) is being reviewed for bowel cleansing.

Dr Philip Katz and colleagues from Pennsylvania, USA reported that this was a phase 3, randomized, multicenter, assessor-blinded, prespecified non-inferiority, head-to-head study.

The team investigated the efficacy, safety, and tolerability of day-before administration of picosulfate and magnesium citrate vs 2L polyethylene glycol solution, and 2 5-mg bisacodyl tablets in adult patients preparing for colonoscopy.

The primary objective was to demonstrate the non-inferiority of picosulfate and magnesium citrate to 2L PEG-3350 and bisacodyl tablets in overall colon cleansing using a modified Aronchick scale.

The doctors also evaluated the efficacy in the ascending, mid, and recto-sigmoid segments of colon using a modified Ottawa scale.

Patient acceptability and tolerability of the bowel preparations were assessed via a standard questionnaire.

Adverse events related to the bowel preparation were reported by 1% of patients
American Journal of Gastroenterology

The research team assessed safety based on the monitoring of adverse events and meaningful findings on clinical evaluations including physical examinations, vital sign measurements, and electrocardiograms.

A total of 603 patients were randomized to receive either picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets.

The team of doctors noted that based on the Aronchick scale, successful overall cleansing was similar in patients receiving picosulfate and magnesium citrate.

Patients receiving 2L PEG-3350 and bisacodyl tablets picosulfate and magnesium citrate demonstrated non-inferiority to 2L PEG-3350 and bisacodyl tablets in overall cleansing of the colon, as measured by the Aronchick scale.

Similarly, the efficacy of picosulfate and magnesium citrate , as measured by the Ottawa scale, was non-inferior to 2L PEG-3350 and bisacodyl tablets in cleansing the ascending, mid, and recto-sigmoid segments of the colon.

The researchers noted that patient-reported acceptability and tolerability for each item examined on the questionnaire was significantly greater for picosulfate and magnesium citrate compared with 2L PEG-3350 and bisacodyl tablets.

Treatment-emergent adverse events related to the bowel preparation reported by 1% of patients receiving picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets were nausea, vomiting, and headache.

No clinically meaningful changes were noted in either treatment arm in data collected from physical examinations, vital sign measurements, and ECGs.

Dr Katz's team commented "When administered as a day-before dose, the bowel cleansing effects of picosulfate and magnesium citrate were non-inferior compared with 2L PEG-3350 and bisacodyl tablets using the clinician-rated Aronchick and Ottawa scales."

"Treatment acceptability was significantly more favorable in patients receiving picosulfate and magnesium citrate  than in patients receiving 2L PEG-3350 and bisacodyl tablets."

Am J Gastroenterol 2013; 108: 401409
20 March 2013

Go to top of page Email this page Email this page to a colleague

 26 May 2015

Advanced search
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Response to sorafenib in hepatocellular carcinoma

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us